Celgene has announced that its Phase III trial, OPTIMISMM, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared pomalidomide (Imnovid®) in combination with bortezomib (Velcade®) and low-dose dexamethasone to bortezomib and low-dose dexamethasone in myeloma patients who had received 1 – 3 prior treatments,…
Results from the Phase III ASPIRE trial show that carfilzomib (Kyprolis®) in combination with lenalidomide (Revlimid®) and dexamethasone has a significant overall survival (OS) benefit in relapsed and refractory myeloma patients. Recently published in the Journal of Clinical Oncology, the results demonstrate that patients receiving carfilzomib, lenalidomide and dexamethasone had a median OS of 48.3…
Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection. Kriegsmann K et al. Biol Blood Marrow Transplant. 2018 Jan 15. pii: S1083-8791(18)30022-3. doi: 10.1016/j.bbmt.2018.01.007. [Epub ahead of print]. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. Anderson K et al. J Clin Oncol. 2018 Jan 17:JCO2017766402. doi: 10.1200/JCO.2017.76.6402. [Epub ahead of…
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma. Tzogani K et al. Oncologist. 2018 Jan 25. pii: theoncologist.2017-0328. doi: 10.1634/theoncologist.2017-0328. [Epub ahead of print]. Immunopathogenesis and immunotherapy of multiple myeloma. Tamura H et al. Int J Hematol. 2018 Jan 24. doi: 10.1007/s12185-018-2405-7. [Epub ahead of print]. Survival of ethnic and racial minority patients with multiple myelomatreated with newer medications.…
Prognostic Value of IL-10 and Its Relationship with Disease Stage in Iranian Patients with Multiple Myeloma. Shekarriz R et al.Asian Pac J Cancer Prev. 2018 Jan 27;19(1):27-32. Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient: Preliminary Results From a Single-center Study. Wu C et al. Acad Radiol. 2018 Jan 16. pii: S1076-6332(17)30518-4. doi: 10.1016/j.acra.2017.12.008.…
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. Dhakal B et al. JAMA Oncol. 2018 Jan 4. doi: 10.1001/jamaoncol.2017.4600. [Epub ahead of print]. Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. Gertz MA et al. Mayo Clin Proc. 2018 Jan;93(1):56-58. doi: 10.1016/j.mayocp.2017.09.012. Prolonged survival after second autologous transplantation and lenalidomide maintenance…
Hemostatic Abnormalities in Multiple Myeloma Patients. Gogia A et al. Asian Pac J Cancer Prev. 2018 Jan 27;19(1):127-130. Incidence of Second Primary Malignancies after Autologous Transplantion for Multiple Myeloma in the Era of Novel Agents. Sahebi F et al. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30021-1. doi: 10.1016/j.bbmt.2018.01.006. [Epub ahead of print]. Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem…
The National Institute of Health and Care Excellence (NICE) has approved the use of daratumumab (Darzalex®) monotherapy as a treatment for relapsed and refractory myeloma patients. This treatment will be made available through the Cancer Drugs Fund (CDF) to patients in England and Wales who have received 3 prior treatments, including a proteasome inhibitor and…
Results from the Phase III TEAMM (Tackling EArly Morbidity and Mortality in Myeloma) trial have recently been reported at the American Society of Haematology 2017 conference. This study assessed the benefit of levofloxacin antibiotic prophylaxis and its effect on healthcare associated infections in newly diagnosed myeloma patients. The results show that levofloxacin prophylaxis had a…
A meta-analysis conducted by researchers at the University of Pennsylvania has shown that treatment with carfilzomib (Kyprolis®) is associated with a higher incidence of cardiovascular events in myeloma patients. The study found that 18.1% of myeloma patients receiving carfilzomib experienced cardiovascular events, including hypertension, cardiac arrest, cardiac failure and arrhythmias, compared to only 3.8% of…